TY - JOUR T1 - Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P2380 AU - Abílio Reis AU - James Twiss AU - Margarida Vicente AU - Fabienne Gongalves AU - Luísa Carvalho AU - Alzira Melo AU - Stephan P. McKena AU - Luís Almeida Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P2380.abstract N2 - Introduction and objectives: Pulmonary arterial hypertension (PAH) is a chronic, progressive and disabling disease affecting quality of life (QoL). The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a PAH-specific questionnaire that includes measures of symptoms, activity limitations and QoL. It was originally developed in English. The main objective of the study was to adapt the CAMPHOR for a Portuguese-speaking population.Methods: A multi-step approach was followed: bilingual and lay panel translation; cognitive debriefing interviews; psychometric testing in repeated postal surveys (two weeks apart); and testing for internal consistency, reproducibility and validity. The Nottingham Health Profile (NHP) questionnaire was used as a comparator instrument to test convergent validity.Results: The CAMPHOR was translated without difficulty by the two panels. During cognitive debriefing interviews, the questionnaire was easily understood and considered relevant to patients' experience with their illness. Psychometric evaluation was performed with 50 PAH patients (47 ± 14 years). Cronbach's alpha coefficients showed that the scales had good internal consistency [Symptoms (S): 0.95; Activities (A): 0.93, QoL: 0.94]. Test-retest coefficients showed that all scales had excellent reliability (S: 0.94; A: 0.89; QoL: 0.93), indicating low levels of random measurement error. The CAMPHOR correlated as expected with the NHP. The magnitudes of correlations followed a similar pattern to those in the original development study.Conclusions: A valid and reliable Portuguese version of CAMPHOR was developed and is recommended for use. ER -